Takeda Pharmaceutical will begin production of Johnson & Johnson's single-dose coronavirus vaccine at IDT Biologika's previously reserved facilities. Takeda previously announced it would provide rapid access to COVID-19 vaccines in Japan through partnerships with Novavax and Moderna. The company will receive technology from Novavax and will be responsible for the development and sale of more than 250 million doses, and will import and distribute 50 million doses of Moderna vaccine.
Takeda Pharmaceutical will begin production of Johnson & Johnson's single-dose coronavirus vaccine at IDT Biologika's previously reserved facilities. Takeda previously announced it would provide rapid access to COVID-19 vaccines in Japan through partnerships with Novavax and Moderna. The company will receive technology from Novavax and will be responsible for the development and sale of more than 250 million doses, and will import and distribute 50 million doses of Moderna vaccine. 
takeda.com
English (US) 